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O B J E C T I V E S This study tested the hypothesis that 4-[18F]ﬂuorophenyltriphenylphosphonium
(18F-TPP) is useful for in vivo positron emission tomography (PET) measurement of mitochondrial
membrane potential (∆m). Its utility as a blood ﬂow tracer also was evaluated.
B A C KG ROUND Tetraphenylphosphonium is useful for in vitro measurement of ∆m. In vivo
measurement of ∆m has potential value in the assessment of heart failure pathophysiology and
therapy as well as assessment of myocardial viability and so may be a very useful clinical tool.
METHOD S Anesthetized swine (N  6) with a balloon catheter in the left anterior descending
coronary artery were studied. Microsphere measurements of myocardial blood ﬂow (MBF) were made
after balloon inﬂation (baseline) and 10 min after intravenous administration of adenosine and
phenylephrine after which 10 mCi 18F-TPP was injected intravenously and dynamic PET data
acquisition obtained for 30 min. After the swine were killed, the hearts were sectioned for microsphere
measurement of MBF and 18F-TPP measured by well counter in these same samples. PET images
provided whole blood and myocardial 18F-TPP concentration for determination of ∆m by the Nernst
equation, corrected for nonspeciﬁc 18F-TPP binding. Microsphere MBF, absolute (ml/min/g) and relative,
was compared with PET data (standard uptake value and K1).
R E S U L T S Nonspeciﬁc binding of 18F-TPP overestimated ∆m measured by 37  4 mV (mean 
SD). Normal zone ∆m of ex vivo samples (91  11 mV; N  52; sample weight, 1.07  0.18 g)
correlated strongly (R2 0.93) with normal zone by PET (81  13 mV). Both ex vivo and PET normal
zone ∆m, although somewhat lower, compared well with that reported for tritium labeled triphenyl-
phosphonium in normal working Langendorff rat heart (100 mV). Although the relative MBF by 18F-TPP
correlated strongly with relative microsphere MBF (R2 0.83), there was no correlation between absolute
MBF by 18F-TPP and microsphere MBF.
CONC L U S I O N S 18F-TPP is a promising tracer for noninvasive PET measurement of ∆m in living
subjects. It is useful as well for assessment of relative but not absolute MBF. (J Am Coll Cardiol Img
2012;5:285–92) © 2012 by the American College of Cardiology Foundation
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etraphenylphosphonium was shown to be
a useful chemical indicator of the mitochon-
drial membrane potential (m) in 1969
(1) and has been used for in vitro studies of
yocardial metabolism (2–7) and tumor imaging
n which differences between normal and malig-
ant cell m are exploited to facilitate tumor
dentification (8). Its specificity for mitochondrial
ccumulation has been established (2). Labeling
f tetraphenylphosphonium with 18F (18F-TPP)
See page 293
for purposes of positron emission tomography
(PET) imaging was recently reported (9). This
study tests the hypothesis that 18F-TPP is useful for
quantitative PET measurement of myocardial
m. Its utility for quantitative measure-
ment of absolute myocardial blood flow
(MBF) also was evaluated.
M E T H O D S
In vitro experiment: human blood. A 15-ml
sample of venous whole blood (WB) was
obtained in heparinized tubes from a hu-
man volunteer and pipetted into 1.5-ml
microcentrifuge tubes to which 18F-TPP
was added in several concentrations. The
WB was mixed at 37°C for 30 min after
which [18F-TPP] (nCi/ml) was measured
in a well counter. Tubes then were centri-
fuged for 10 min at 5,000 g after which
plasma was transferred into a 1.5-ml mi-
crocentrifuge tube and [18F-TPP] mea-
sured. The tube of packed red cells was
reweighed and [18F-TPP] measured. All measure-
ents were corrected for physical decay.
In vivo experiment: domestic swine. After overnight
fast, the swine (40 kg) were sedated with Telazol
(tiletamine) (4.4 mg/kg) and xylazine (2.2 mg/kg)
intramuscularly, intubated, and then maintained on
isoflurane anesthesia (1% to 3%) and oxygen for the
entire experiment (N  6).
Groin sites were used to insert catheters in right
and left femoral arteries and veins. The right
femoral vein was used to place a catheter by trans-
septal technique in the left atrium. This catheter
was used to administer neutron-activated, radiola-
beled microspheres (15 m diameter, 9  106
spheres/injection). Catheters in the right and left
femoral arteries were used to monitor arterial pres-
l-
ing
w
d
ion
ure
esure and for reference withdrawal of blood (for 2 (min at 10 ml/min) for microsphere measurements
of MBF. Catheters placed in the left femoral vein
and right external jugular vein were used for admin-
istration of drugs and 18F-TPP.
The right internal carotid artery was accessed by
cut down and used to insert a 6-F “hockey stick”
catheter under fluoroscopic control to the left an-
terior descending coronary artery (LAD). Next, an
angioplasty catheter with a 2.75  15-mm balloon
as passed through the hockey stick catheter and
ositioned in the mid to distal third of the LAD.
he angioplasty balloon was partially inflated suf-
cient to produce an 1- to 2-mm ST-segment
levation in anterior precordial electrocardiography
eads. An amiodarone drip (1 mg/min) was begun
efore balloon inflation after an intravenous loading
ose of 150 mg. A lidocaine drip at 2 mg/min also
as begun after the loading dose of 50 to 100 mg
ntravenously. Phenylephrine was given intrave-
ously to maintain systolic arterial pressure (SAP)
t 110 to 120 mm Hg.
Experimental protocol. In the PET laboratory, base-
ine hemodynamics and pulse oxymetry (O2 and
CO2) were recorded and microspheres injected in
the left atrium. Next, adenosine was begun at 140
g/kg/min intravenously and phenylephrine in-
creased to increase the SAP to 150 to 170 mm Hg.
Once a stable, a second injection of microspheres
was given. Immediately after completion of the
reference blood withdrawal, dynamic PET imaging
acquisition was begun, and approximately 5 to 10 s
later, 10 mCi 18F-TPP was injected intravenously.
The phenylephrine infusion was adjusted to main-
tain a constant SAP. Adenosine infusion continued
throughout the 30-min dynamic PET acquisition
(8 frames @ 15 s/frame, 8 frames @ 1 min/frame
and 10 frames @ 2 min/frame). Hemodynamic and
pulse oxymetry data were recorded at 2- to 5-min
intervals throughout the study.
At the end of the PET imaging acquisition, the
angioplasty balloon was fully inflated and blue dye
injected to assist in marking the LAD territory
distal to the balloon. The animals were killed by
pentobarbital overdose (200 mg/kg intravenously).
Subsequently, the chest of each swine was opened
and the position of the balloon documented with
sutures and photographed in situ. Next, the heart
was removed, photographed, and sectioned for
counting of 18F-TPP in a region distal to the LAD
alloon (distal zone), adjacent to the balloon (bor-
er zone) and proximal to the balloon on the high
nterolateral wall and in the posterobasal segmentA B B R E V I A T I O N S
A N D A C R O N YM S
BZ border zone
18F-TPP
-[18F]fluorophenyltripheny
phosphonium
LAD left anterior descend
coronary artery
LV left ventricular
MBFmyocardial blood flo
MBFadomyocardial bloo
flow during adenosine infus
NZ normal zone
PET positron emission
tomography
SAP systolic arterial pressnormal zones). These same tissue samples were
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MBF (BioPal, Worcester, Massachusetts).
PET image analysis. PET images were reconstructed
sing a filtered back-projection technique (10).
ircular regions of interest (3-pixel diameter) were
laced over the following areas of 4 adjacent mid
eft ventricular (LV) transaxial sections; LV cavity,
istal zone (infarct zone), border region (BZ), and
igh anterolateral and posterobasal normal zones
NZs). Decay-corrected time activity curves were
enerated over each region of each section and then
veraged to obtain a single time activity curve for
ach. The time activity curves obtained for each NZ
hen were fit to a 2-compartment tracer kinetic
odel (KIS program, UCLA Department of Mo-
ecular and Medical Pharmacology, Computational
ciences Group [11]) to obtain values of K1.
Computation of m: 18F-TPP correction factor. 18F-
PP bound to lipid cell membranes is unavailable
or distribution according to the Nernst potential
nd must be accounted for to properly estimate
m (3,4,6). Thus, we identified tissue samples
ith baseline MBF 0.05 ml/min/g for 	3 h,
hich represent infarcted myocardium (12), and so
ad zero cytosolic and mitochondrial membrane
otentials. The Nernst equation was applied to
ompute m in these samples.
 mV  1,000 K  ln 18F-TPPout ⁄
18F-TPPin
where K  (R · T)/(z · F) (R is the universal gas
constant [8.314 J · K1 · mol11; joules per kelvin
er mole]; T is temperature in kelvin [K  °C 

73.15]; z is the valence of the ionic species; 
1 for
; F is Faraday’s constant [96,485 C · mol1;
oulombs per mole]).
Plasma [18F-TPP] was set equal to 0.95 times
that measured in the LV blood pool by PET.
Concentration of tracer in the cardiomyocyte cyto-
sol was obtained from Equation 1, which used
plasma concentration as [out] and a time averaged
cell membrane potential of 15 mV (see the
following) to solve for the cytosolic concentration
[in]. Time-averaged cell membrane potential was
obtained by integration of a typical myocardial
action potential (phases 0 to 4, with a duration of
400 ms [average measured QT in the present study]
and R-R 600 ms [average heart rate during the late
phase of the PET data acquisition in the present
study]). Values of the resting cell membrane poten-
tial (75 mV) and magnitude of the peak at phase
0 (
80 mV) were based on data in the literature13). The cytosolic [18F-TPP; out] in conjunction
ith ex vivo measured myocardial [18F-TPP; in]
as used to compute m by Equation 1. Because
he effective mitochondrial matrix volume is ap-
roximately 0.1 ml/g myocardium (14–16) and
yocardial tracer concentration is given in nanocu-
ies per milliliter, the ex vivo measured myocardial
18F-TPP] was multiplied by a factor of 10.5 to
account for myocardial tissue density of 1.05 g/ml
(16), and the mitochondrial matrix volume it was
present in. The m computed in infarcted myo-
ardium reflects nonspecific tracer binding and was
ubtracted from m computed for NZs and BZs.
Comparison of 18F-TPP myocardial retention and MBF.
The relationship between myocardial [18F-TPP]
nd MBF during adenosine infusion (MBFado)
as made by comparing the well counter–based
yocardial SUV (nCi/ml)/(injected dose)/(kg) with
BFado (microsphere data) in the same tissue
amples. Data were expressed both in absolute and
elative terms (normalization to highest value of
UV and MBFado in a given animal).
Statistical methods. Data are expressed as mean  1
SD. Hemodynamic parameters were analyzed by
1-way analysis of variance for repeated measure and
Newman-Keuls multiple comparison test. A paired
t test (2 tailed) was used to compare differences
between baseline and hyperemic MBF and between
NZ and BZ m. Linear regression analysis was
used to assess the correlation between SUV 18F-
PP and MBFado. Values of p  0.05 were
onsidered statistically significant.
Table 1. Hemodynamics, Pulse Oxymetry, and MBF
Neo A
At Rest Ado TPP Sta
HR, min1 84 9 91 10 94 9
SAP, mm Hg 119 12 152 18 149 1
RPP, 100 100 18 138 26 141 2
Pulse oxymetry, %
Oxygen 98 2 97 2 98 3
CO2 36 2 36 3 35 4
MBF, ml/min/g
ANTNZ 1.04 0.44 4.01 3.67*
PSTNZ 0.99 0.35 3.68 3.34*
ANTBZ 0.60 0.29 1.49 1.28‡
APXIZ 0.11 0.11 0.25 0.31‡
Values are mean  SD; n  6 swine. *p  0 .05 versus at rest. †p  0.01 versus
without balloon inﬂated was excluded (n  5).
Ado  adenosine; ANTBZ  anterior border zone; ANTNZ  anterior normal
infarct zone; HR heart rate; MBFmyocardial blood ﬂow; Neo phenylephrin
normal zone; RPP  rate pressure product (mm Hg · s); SAP  systolic artedo  Neo
rt TPP End
105 9*
8 153 15†
4 161 22*
99 1
36 3
at rest. ‡One animal
zone; APXIZ  apex
e; PSTNZ posterior
rial pressure; TPP 18F-tetraphenylphosphonium.
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288R E S U L T S
In vitro data: 18F-TPP and human blood. Plasma/WB
18F-TPP] ratio was 0.95  0.04 (15 samples).
In vivo data: hemodynamics, oxymetry, and MBF.
Heart rate increased modestly during the study (p 
0.05) compared to the baseline measurement. As
intended, SAP increased significantly versus rest (p 
0.01) with the start of adenosine (phenylephrine
dose increased), and remained increased at a steady
level during image acquisition. Accordingly, rate
pressure product also increased significantly versus
rest (p  0.01) but did not change significantly
uring imaging. Arterial pulse oxymetry demon-
trated stable normal values of O2 and CO2
NZ In Vivo Versus Ex Vivo m
ne (NZ) mitochondrial membrane potential (∆m) in vivo is
imal number on abscissa) and compared with ex vivo determina-
on well counter measurement of myocardial 4-[18F]ﬂuorophenyl-
hosphonium. Correlation was excellent (R2 0.93, p  0.01).
In Vivo m
ochondrial membrane potential (∆m) is shown for the normal
and border zone (BZ) of 5 animals. NZ ∆m (82  14 mV) dif-
ﬁcantly from that of BZ (66  17, p  0.05). Note: 1 animal was0
hat did not have BZ.throughout the study (Table 1). MBF data at rest
and with adenosine in the NZ, BZ, and infarct zone
are shown in Table 1. Importantly, BZ MBF at rest
(0.60  0.29) was reduced versus averaged anterior
and posterior NZ MBF at rest (0.96  0.41, p 
0.05).
Ex vivo data: nonspeciﬁc binding of 18F-TPP in in-
farcted myocardium. In infarcted myocardium,
m was 37  4 mV (14 tissue samples; 4
animals; sample weight, 1.03  0.23 g). Applica-
tion of the correction factor reduced NZ m to
71  3% of the uncorrected value (corrected 
91  11 mV; 52 tissue samples; 6 animals; sample
weight, 1.07  0.18 g).
In vivo data: 18F-TPP m and MBF. NZ m was
81  13 mV and correlated very closely with that
etermined in normal myocardium ex vivo (R2
.93, p  0.01) (Fig. 1). BZ m could not be
etermined in 1 animal due to uncontrollable ven-
ricular tachycardia/ventricular fibrillation during
AD balloon inflation; therefore, it remained de-
ated. Thus, BZ m was lower than NZ in 5of 5
wine (66  17 vs. 82  14, respectively; p 
.05) (Fig. 2). There was no correlation between
bsolute rest MBF and m for all NZs and BZs
R2 0.001, p  NS). Further, the BZ:NZ m
atio (0.80  0.13) exceeded the BZ:NZ MBFado
atio (0.59 0.24, p 0.03) and the BZ:NZ MBF
t rest ratio (0.65  0.27, p  0.17). The LAD
alloon was inflated 3.4  1.0 h before the start of
maging. Accordingly, anteroapical distal zones
ere composed primarily of infarcted myocardium
rest MBF, 0.11  0.11 ml/min/g) (Table 1), and
o computation of m was not appropriate.
Ex vivo data: 18F-TPP SUV and MBF. As shown in
Figure 3A, the correlation between normalized
18F-TPP SUV and normalized MBFado was quite
strong at the extremes of the range and somewhat
more variable in the mid range. Overall, R2  0.83
(p  0.001). There was no correlation between
bsolute SUV and absolute MBFado (Fig. 3B).
In vivo data: 18F-TPP K1, SUV, and MBF. Time activity
curves (LV blood pool and anterior myocardial NZ)
are shown in Figure 4. Tracer kinetic model fit for
NZs was excellent (R2  0.83  0.10; F4,22  37.7 
8.9; and p 7.01E-05 2.41E-04). Values of K1
or NZs on transaxial images (0.28  0.08; range,
.13 to 0.40) demonstrated no correlation with abso-
ute MBFado over a wide range of flows (Fig. 5).
hus, values of K1 (transposed visually from values
omputed on transaxial slices) for anterior and
osterior/inferior NZs of animal 011311 (Fig. 6A;Figure 1.
Normal zo
shown (an
tion basedFigure 2.
In vivo mit
zone (NZ)
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289was 10.00 ml/min/g and 9.06 ml/min/g, respec-
tively, were similar (0.35 and 0.40, respectively) to
those for the animal (animal 010611, Fig. 6B) in
which the MBFado was 1.23 ml/min/g and 1.33
ml/min/g, respectively. Finally, the NZ first-pass
tracer extraction fraction computed from K1/
MBFado was 0.19  0.19.
D I S C U S S I O N
We tested the hypothesis that quantitative PET
imaging of 18F-TPP is useful for in vivo measure-
Figure 3. Ex Vivo Data for 18F-TPP SUVnrm Versus MBFnrml
and 18F-TPP SUVabs Versus MBFabs
(A) The strong correlation (R2  0.83, p  0.001) between rela-
tive 4-[18F]ﬂuorophenyltriphenylphosphonium (18F-TPP) standard
uptake value (SUV) determined by a well counter and relative
myocardial blood ﬂow (MBF) during adenosine infusion determined
by microspheres in the same tissue samples (95% conﬁdence inter-
vals shown) is demonstrated. In contrast, there was no correlation
between absolute (abs) values of SUV and MBF during adenosine
infusion (B). nrm  normal.ment of myocardial m. Although data on in vivo measurement of normal m in an intact animal
are not available, measurements have been made
using tetraphenylphosphonium in a working Lan-
gendorff rat heart model (6,7). Measured m
varied as a function of metabolic substrate and
workload. Thus, with glucose (11 mM) perfusate
and low workload, m equaled 118 mV versus
100 mV at high workload (p  0.05) (7). How-
ver, when pyruvate was used, m equaled 145
V at low workload and 116 mV at high work-
oad (p 0.05) (7). The investigators attributed the
ifferences in m between substrates to “higher
ytosolic phosphorylational potentials in the pyru-
ate perfused hearts” (6,7). Increased myocardial
xygen consumption associated with increased work-
oad resulted in a reduction in m relative to low
orkload, which the investigators attributed to “accel-
ration of ATP synthesis which may be due
o modification of the properties of the ATP synthase”
7). Electron transport complex 5 is responsible for the
ransport of protons into the mitochondrial matrix
here they associate with adenosine triphosphate
ynthase in phosphorylating adenosine diphosphate
17). Thus, m would be expected to decrease (less
egative) under conditions of increased cardiac work,
hich requires increased adenosine triphosphate syn-
hesis. In the present study, measured NZ m of ex
ivo samples (91 11 mV) correlated strongly (R2
0.93) (Fig. 2) with NZ in vivo by PET (81  13
V) and agreed well with that of glucose or pyruvate
erfused Langendorff rat heart under high workload
onditions (100 and116 mV) (7), which prevailed
n the present study as evidenced by sinus tachycardia
105/min) and systemic hypertension (SAP  153).
Not only was workload increased, but isofluorane
was used for general anesthesia and adenosine infused
throughout PET data acquisition. Isofluorane and
adenosine either alone or in combination induce
ischemic preconditioning (18) by mitochondrial KATP
channel activation (19,20), which decreases (less neg-
ative) m (21,22). Accordingly, several factors in
the current study worked to lower measured m
compared with an often-cited “normal” level (180
mV [17]) measured in isolated mitochondrial prepa-
rations. Finally, reduced BZ m versus NZ (Fig. 2)
likely reflects an important effect of 3.5 h of isch-
mia modified as noted previously such that the levels
f NZ and BZ m tended to approach one another
i.e., came closer to the same level). Had m
ifferences simply reflected differences in MBF per se
t the time of tracer administration, then the BZ:NZ
m ratio should have closely matched BZ:NZ
0b
m
c
K1 would
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290MBFado ratio but in fact did not (0.80  0.13 vs.
.59  0.24, respectively; p  0.03).
Previous PET work with 18F-TPP suggested its
potential value for MBF measurement (9). The pres-
ent study demonstrates that it is a good indicator of
relative flow in a given individual (Figs. 3A, 6A, 6B)
ut fails to support its use for quantitative measure-
ents of absolute MBF (Fig. 3B). Its lipophilic
ationic nature and low K1 (0.28  0.08; range, 0.13
to 0.40) suggest that it enters the myocyte by diffusion,
similar to sestamibi (23), and concentrates in mito-
chondria in accordance with the Nernst potential
(2,3,8). The very low extraction fraction (0.19) leads to
severe tracer “roll off” as flow increases (Fig. 3B) and
Normal Zones: K1 (2-Compartment Model)
nship between normal zone K1 and absolute myocardial blood
g adenosine infusion (MBFado) is shown. K1 is low (0.28  0.08)
correlate with MBFado over a wide range of ﬂows. A perfect
would have an extraction fraction (ExF) equal to 1, in which case,
Figure 4. 18F-TPP NZ and LV Blood Pool TACs
Typical time activity curves (TACs) of the NZ (yellow diamonds)
#010611 are shown. The inset shows the curves on an expanded
phonium (18F-TPP) injection, NZ activity remained constant. LV blo
stant after 10 min.f
correlate exactly with MBF because K1  MBF · ExF.so precludes accurate quantitative measurement of
absolute MBF.
Clinical implications. Measurement of m in liv-
ing subjects may contribute greatly to under-
standing the pathophysiological mechanisms and
improving therapy in heart failure. Heart failure
associated with hypertension, diabetes, and met-
abolic syndrome has been causally related to
abnormalities of myocardial fatty acid and carbo-
hydrate metabolism with resulting impaired en-
ergy production (24 –29). Metabolic therapy to
improve energy production in heart failure was
reported in a canine model (30) as well as in humans
(31,32). One study demonstrated positive results (32),
but another produced negative results (31). Editorials
accompanying each indicated that mechanisms of
impaired energy production were uncertain but sug-
gested that impaired glucose utilization was likely
involved (27,33). Additionally, factors that may play a
role include interactions among mitochondrial uncou-
pling proteins, the adenine nucleotide translocator,
and mitochondrial membrane transition pore (33), all
of which may cause depolarization of the inner mem-
brane, impair energy production, and cause ATP syn-
thase to run in reverse. Trimetazidine may ameliorate
heart failure and increase myocardial efficiency (32) by
reversing 1 or more of these pathophysiological mecha-
nisms (33). Accordingly, measurement of m has the
potential to contribute importantly to our understanding
of metabolic mechanisms active both in the pathophys-
iology of and metabolic therapy for heart failure.
Study limitations. There is no gold standard method
left ventricular (LV) blood pool (green squares) of animal
le. Beginning at 2 min after 4-[18F]ﬂuorophenyltriphenylphos-
activity declined rapidly after injection and then remained con-Figure 5.
The relatio
ﬂow durin
and fails to
MBF tracerand
sca
odor in vivo measurement of myocardial m.
C
p
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measured in a working Langendorff rat heart model
(7). Further, in vivo measurement of m corre-
lated very closely with ex vivo measurements in
which the tracer concentration was precisely known
and thus serves as an independent, experimentally
determined indicator of the validity of the PET
methodology (Fig. 2). Finally, studies of m
that used fluorophore methodology (17,34,35) of
isolated cardiomyocytes indicate that within a
given cell (40% mitochondria by volume [36])
there is a considerable range of m (34). Thus,
any single value obtained with the present meth-
odology in an intact, living subject will reflect the
average of a very large number of mitochondria, a
fact that has both advantages and potential
Figure 6. 18F-TPP Vertical Long Summed Image
Vertical long-axis 18F-TPP summed images from 2 study animals.
were similar in both animals (0.27 and 0.26, respectively, PIG #01
differed greatly (PIG #011311: 10.00 and 9.06 ml/min/g, respectiv
Abbreviations as in Figures 3 and 5.1969;222:1076–8. Mol Biol 1984;43:1C O N C L U S I O N S
The data obtained indicate that 18F-TPP is useful for
quantitative in vivo PET measurement of m. The
value of the NZ m observed agreed well with that
measured with tetraphenylphosphonium in a working
Langendorff rat heart model (7). Additional in vivo
studies that perturb m in a known direction (e.g.,
partially depolarized in ischemic preconditioning
[37–39] or hypoxia) are necessary to further assess the
validity of PET 18F-TPP methodology for m
measurement.
Reprint requests and correspondence: Dr. Henry Gewirtz,
ardiac Unit/Yawkey 5E, Massachusetts General Hos-
ital, 55 Fruit Street, Boston, Massachusetts 02114.
hough values of K1 for anterior and inferoposterior segments
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